1. Upregulation of DEAD box helicase 5 and 17 are correlated with the progression and poor prognosis in gliomas.
- Author
-
Luo, Qisheng, Que, Tianshi, Luo, Hongcheng, Meng, Yiliang, Chen, Xiaoping, Huang, Haineng, Hu, Rentong, Luo, Kunxiang, Zheng, Chuanhua, Yan, Peng, Gong, Juxin, Fu, Huangde, Liu, Jia, Tang, Qianli, and Huang, Guanglong
- Subjects
- *
PROGRESSION-free survival , *IMMUNOSTAINING , *PROGNOSIS , *TUMOR diagnosis , *BOXES , *STATISTICS - Abstract
Recent researches indicated Ddx5 and Ddx17 play crucial roles in tumorigenesis. However, the study of Ddx5 and Ddx17 in glioma remains a little. Our study investigated their expression in glioma and evaluated its association with clinical factors and prognostic significance. The expression of Ddx5 and Ddx17 were both upregulated in glioma tissues compared to normal brain tissues, and a significant positive correlation between Ddx5 and Ddx17 expression was identified by statistical analysis. Immunohistochemical staining verified the expression of Ddx5 and Ddx17 in peritumoral zone was lower than that in core zone but higher than normal brain tissues. Moreover, the increased expression of Ddx5 and Ddx17 was markedly correlated with WHO Grade and histological type, and high Ddx5 and Ddx17 were found to be significantly associated with the worse overall survival of glioma patients. In additional, higher expression of both Ddx5 and Ddx17 predicted shorter clinical survival time for high-grade glioma patients with radiotherapy or with chemotherapy. In conclusion, overexpressed Ddx5 and Ddx17 are involved in the clinical progression and poor prognosis of glioma patients, suggesting that their upregulation can be used as a reliable clinical predictor for tumor diagnosis and to predict survival in patients with glioma. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF